Lapatinib: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
David Canner (talk | contribs)
7,699 edits
No edit summary
Joel L. Sussman (talk | contribs)
ConfirmAccount, Editor, Mutation, Print3D, Tester, Bureaucrats, journal, tester
11,713 edits
No edit summary
 
(9 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<applet  load="" size="480" color="" frame="true"  spin="on" Scene ="Lapatinib/Lapatinib/2" align="right" caption="Lapatinib, also known as Tykerb ([[3bbt]])"/>
<StructureSection load='' size='450' side='right' scene='Lapatinib/Lapatinib/2' caption='Lapatinib, also known as Tykerb ([[3bbt]])'>
__TOC__
===Better Known as: Tykerb===
===Better Known as: Tykerb===
* Marketed By: GlaxoSmithKline
* Marketed By: GlaxoSmithKline
Line 6: Line 7:
* Date of FDA Approval (Expiration): 2007 (2017)
* Date of FDA Approval (Expiration): 2007 (2017)
* 2009 Sales (Projected Peak): $150 Million ($4.5 Billion)<ref>http://money.cnn.com/2006/06/03/news/companies/glaxo_breastcancer/index.htm</ref>
* 2009 Sales (Projected Peak): $150 Million ($4.5 Billion)<ref>http://money.cnn.com/2006/06/03/news/companies/glaxo_breastcancer/index.htm</ref>
* Importance: It is one of the newest treatments for cancer. Complaints over the high cost ($22,000) for a treatment course which only prolongs survival in breast cancer patients by less than 2 months. It is particularly effective against HER2-positive breast cancer.  
* Importance: It is one of the newest treatments for cancer. Complaints over the high cost ($22,000) for a treatment course which only prolongs survival in breast cancer patients by less than 2 months. It is particularly effective against HER2-positive breast [[cancer]].  
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders


Line 13: Line 14:


===Pharmacokinetics===
===Pharmacokinetics===
{| class="wikitable" border="1" width="55%" style="text-align:center"
<table style="background: cellspacing="0px"  align="" cellpadding="0px" width="50%">
|-
<tr>
!  colspan="4" align="center"| EGFR Inhibitor [[Pharmacokinetics]] Comparison at Equivalent Dosages<ref>PMID:16609030</ref><ref>PMID:17482782</ref><ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref>
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
|-
<div style="height:100%; width: 100%">
! Parameter
{{:Tyrosine Kinase Inhibitor Pharmacokinetics}}
! [[Erlotinib]] <br/>(Tarceva)
</div>
! [[Gefitinib]] <br/>(Iressa)
</td>
! [[Lapatinib]] <br/>(Tykerb)
</tr>
|-
</table>
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
</StructureSection>
! 2.0
! 5.4
! 4
|-
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
! 69.6
! 130
! 115
|-
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
! 99
! 59
! Variable
|-
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
! 93
! 90
! 99
|-
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! 9.4
! 26.9
! 9.6
|-
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! 20577
! 3850
! 1429
|-
! Typical Dosage (mg)
! 150
! 250
! 100
|-
! Metabolism
! Hepatic - (CYP3A4)
! Hepatic - (CYP3A4)
! Hepatic - (CYP3A4)
|}
 
===References===
===References===
<references/>
<references/>
__NOEDITSECTION__
__NOEDITSECTION__
__NOTOC__
Retrieved from "https://proteopedia.org/Lapatinib"